P124 Effusion Size on the Chest Radiograph at Day 7 Post-Pleural Drainage is a Good Predictor of Size at 3 Months, Regardless of Initial Intrapleural Therapy. (19th November 2012)

• Record Type: Journal Article
• Authors: Hallifax, RJ; Nagendran, M; Maruthappu, M; Manuel, A; Wrightson, JM; Maskell, NA; Davies, HE; Rahman, NM
• Is Part Of: Thorax. Volume 67(2012)Supplement 2
• Page Start: A116
• Page End: A116
• Publication Date: 2012-11-19
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2012-202678.407
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Introduction: Drainage of infection pleural fluid is essential in improving patient outcomes. The MIST-2 Trial (NEJM 2011) demonstrated intrapleural tissue plasminogen activator (t-PA) and DNase therapy improves drainage in patients with pleural infection from Day 1 to 7 compared to placebo. However, there is no evidence assessing whether this difference is sustained at 3 months. Methodology used in the MIST-2 trial demonstrated that a digital chest radiograph measurement strategy was an effective measurement of pleural fluid volume and correlated closely with computed tomography scanning in estimating effusion size. Aims: To determine whether intrapleural treatment with t-PA, DNase, or both, showed a sustained significant difference in effusion size at 3 months. To assess predictors of residual pleural shadowing 3 months post treatment. Methods: 132/193 (68%) patients in the MIST-2 trial had assessable chest radiographs at 3 months (remaining patients were lost to follow-up or died). Effusion size was measured as a percentage of the hemithorax occupied on digital radiograph image (JPEG format). Each image was analysed independently by a medical student and respiratory specialist. Where the difference in estimates exceeded 2%, the radiographs were reassessed together to generate consensus. Analysis was blind to treatment arm. Results: There was no significant difference between placebo and any treatment group in the 3 month radiology outcome. The 3 month effusion size was positively correlated with that at Day 7 (Pearsons 0.27, p=0.003). Neither Day 1 effusion size, nor the difference between Day 1 to 7 was significantly correlated with 3 month outcome. Linear regression analysis demonstrated significant correlation for Day 7 effusion size with 3 months size (p=0.004), but non-significance by treatment arm (p=0.071). Conclusions: In those that survive and have a chest radiograph at 3 months, there is no difference in the radiological outcome at 3 months between treatment groups on the basis of treatments given, including surgical intervention. However, the appearance at day 7 is significantly correlated with the 3 month chest radiograph. Further statistical modelling of this data is now required to assess the relative contributions of intrapleural interventions and surgery in those that survive to 3 months.